아세틱/리놀레익/팔미틱트라이글리세라이드
9,12-Octadecadienoic acid (9Z,12Z)-, 1-((acetyloxy)methyl)-2-((1-oxohexadecyl)oxy)ethyl ester
기본 정보
- CAS
221139-79-3- 표준 SMILES
CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC(COC(C)=O)COC(=O)CCCCCCCCCCCCCCC- InChIKey
GAKUNXBDVGLOFS-DUZKARGPSA-N- 분자식
- C39H70O6
- 평균 분자량
- 635 g/mol
- 단동위원소 질량
- 634.51723995
개요
Mosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.
이름 및 식별자
- 우선 이름
- 9,12-Octadecadienoic acid (9Z,12Z)-, 1-((acetyloxy)methyl)-2-((1-oxohexadecyl)oxy)ethyl ester
- IUPAC
- (1-acetyloxy-3-hexadecanoyloxypropan-2-yl) (9Z,12Z)-octadeca-9,12-dienoate
- 현지명
- 아세틱/리놀레익/팔미틱트라이글리세라이드
- 영어명
- EC-18 221139-79-3
- 분자식
- C39H70O6
- 분자량
- 634.97
이름 및 동의어
Mosedipimod [USAN]PLA-racglycerolEC-18 cpdPlag, (+/-)UNII-88928BS57EWHO 10702(1-acetyloxy-3-hexadecanoyloxypropan-2-yl) (9Z,12Z)-octadeca-9,12-dienoate1-palmitoyl-2-linoleoyl-3-acetyl-rac glycerol9,12-Octadecadienoic acid (9Z,12Z)-, 1-((acetyloxy)methyl)-2-((1-oxohexadecyl)oxy)ethyl ester(9Z,12Z)-1-Acetoxy-3-(palmitoyloxy)propan-2-yl octadeca-9,12-dienoatePLAGMOSEDIPIMOD [INN]
이름 더 보기
아세틱/리놀레익/팔미틱트라이글리세라이드Mosedipimod1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerolMosedipimod EC-18EC-18 221139-79-31-Palmitoyl-2-linoleoyl-3-acetylglycerol9,12-Octadecadienoic acid (9Z,12Z)-, 1-[(acetyloxy)methyl]-2-[(1-oxohexadecyl)oxy]ethyl ester
Mosedipimod (USAN/INN)MOSEDIPIMOD [WHO-DD]SCHEMBL974869CHEMBL157366orb1699911GAKUNXBDVGLOFS-DUZKARGPSA-NDTXSID901370308GLXC-25910
데이터베이스 식별자
- CAS
221139-79-3- PubChem CID
- 9960925
- DTXSID
DTXSID901370308- ChEMBL
CHEMBL157366- UNII
- 88928BS57E
- Nikkaji
- J2.068.029F
물성
구조 계산 물성
- XLogP
- 14.1
- 극성 표면적
- 78.9 Ų
- 수소 결합 공여자 수
- 0
- 수소 결합 수용자 수
- 6
- 회전 가능 결합 수
- 36
- 무거운 원자 수
- 45
- 형식 전하
- 0
- 복잡도
- 744
물리화학적 성질
- 끓는 점
- 650.6 · 650.6±35.0 °C(Predicted)
- 밀도
- 0.947 · 0.947±0.06 g/cm3(Predicted)
- 화장품 원료 기능
- 보습제피부 컨디셔닝피부 컨디셔닝 - 보습제
화학 및 산업
약리 정보
Mechanism of Action
Mosedipimod is a proprietary compound originally derived from Sika deer antler. It accelerates endocytic trafficking of Pattern Recognition Receptors which allows for the swift removal of PAMPs/DAMPs. This drug has been shown to improve lung function and reduce inflammation and fibrosis in animal models. Currently, mosedipimod is being investigated against chemoradiation-induced oral mucositis and neutropenia, as well as against COVID-19.
관련 반응
1건
화합물 노트
불러오는 중…